Key facts
- Notable investors include Shenzhen GTJA Investment Group.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Medipure
- ·The full record, as it builds
Funding rounds
No funding rounds for Medipure are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Medipure
Provider of genetic testing and health management services intended to support early disease detection and preventive healthcare. The company's services include non-invasive gut microbiome gene testing and personalized health solutions, characterized by proprietary bioinformatics platforms, advanced microbial gene sequencing technologies, and tailored health management plans, enabling the provision of accurate disease risk assessments and customized health recommendations suitable for individuals seeking proactive health management.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2021
- Ownership
- Privately Held (backing)
Medipure doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Medipure shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Medipure in its N-PORT filings yet. We sweep new filings monthly.